Clinical Trial Update: A Phase II/III Trial of Human Anti-CMV Monoclonal Antibody MSL 109 (MACRT) [Phase 2]

View source ↗

Summary

This document provides an update on a Phase II/III trial evaluating the human anti-CMV monoclonal antibody MSL-109 (MACRT) for cytomegalovirus retinitis in HIV-…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cytomegalovirus Retinitis
• HIV Infection

Drugs mentioned

• MSL 109 (MACRT) (MSL-109 monoclonal antibody against CMV)

Snippet

Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) | Conditions: Cytomegalovirus Retinitis, HIV Infections | Phase 2 | Status: COMPLETED